Markets
GSK

Glaxo (GSK) Q3 Earnings Surpass Estimates, Revenues In Line

GlaxoSmithKline plc GSK , one of the largest health care companies, reshaped its business following the Mar 2015 completion of the three-part, inter-conditional transaction with Novartis related to its Consumer Healthcare, Vaccines and Oncology businesses. Under the deal, Glaxo sold its oncology assets to Novartis and acquired Novartis' Vaccines business (excluding influenza vaccines). Additionally, the companies created a joint venture (JV), thereby combining their consumer divisions to form a larger consumer health care business.

Following the completion of the deal, the UK-based company now focuses on its three core businesses - Pharmaceuticals (respiratory, HIV), Vaccines (pediatric, adolescent, adult, and travel vaccines) and Consumer Healthcare (wellness, oral health, nutrition and skin health products).

However, like many of its peers, Glaxo is facing challenges in the form of increasing competition, genericization and pricing pressure in major markets.

In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential, restructuring and cost-cutting initiatives and performance of new products apart from the usual top-and bottom-line numbers.

Glaxo's performance has been pretty good so far, with the company's earnings beating expectations thrice in the trailing four quarters while posted in-line results in another. Overall, the company has delivered an average positive surprise of 8.34%.

GlaxoSmithKline PLC Price and EPS Surprise

GlaxoSmithKline PLC Price and EPS Surprise | GlaxoSmithKline PLC Quote

Currently, Glaxo has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings Beat: Glaxo reported core earnings of 85 cents per American depositary share, which beat our consensus estimate of 81 cents.

Revenues In-line: Revenues were up 2% year over year at constant exchange rate (CER) to $10.2 billion (£7.8 billion). Revenues were in line with Zacks Consensus Estimate.

Key Stats: Sales in the quarter were driven by strong performance mainly in the Consumer Healthcare and Pharmaceuticals segments which were up 2% at CER. Sales of the Vaccines segment were flat at CER.

2017 Guidance: Glaxo maintained its core 2017 earnings growth at 3-5% CER, with no Advair generics expected to be launched this year.

Share Price Impact: In-active in pre-market trading .

Check back later for our full write up on GSK earnings report later!

Zacks' Hidden Trades

While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?

Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.

Click here for Zacks' secret trade>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

GlaxoSmithKline PLC (GSK): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GSK

Other Topics

Earnings Investing Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More